CYP Induction-Mediated Drug Interactions: in Vitro Assessment and Clinical Implications
The DOI matches its Crossref record; 256 of the 257 references it cites were found in a registry or an index.
Abstract
Cytochrome P450 (CYP) induction-mediated interaction is one of the major concerns in clinical practice and for the pharmaceutical industry. There are two major issues associated with CYP induction: a reduction in therapeutic efficacy of comedications and an induction in reactive metabolite-induced toxicity. Because CYP induction is a metabolic liability in drug therapy, it is highly desirable to develop new drug candidates that are not potent CYP inducer to avoid the potential of CYP induction-mediated drug interactions. For this reason, today, many drug companies routinely include the assessment of CYP induction at the stage of drug discovery as part of the selection processes of new drug candidates for further clinical development. The purpose of this article is to review the molecular mechanisms of CYP induction and the clinical implications, including pharmacokinetic and pharmacodynamic consequences. In addition, factors that affect the degree of CYP induction and extrapolation of in vitro CYP induction data to in vivo situations will also be discussed. Finally, assessment of the potential of CYP induction at the drug discovery and development stage will be discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Items 201–256 of 256
Kedderis, L. B., Mills, J. J., Andersen, M. E., & Birnbaum, L. S. (1993) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1993.1132 · Cited by 69
Kall, M., & Clausen, J. (1995) · Human & Experimental Toxicology · doi:10.1177/096032719501401004 · Cited by 69
Dilger, K., Greiner, B., Fromm, M. F., Hofmann, U., Kroemer, H. K., & Eichelbaum, M. (1999) · Pharmacogenetics · doi:10.1097/00008571-199910000-00002 · Cited by 69
Induction of Cytochrome P450 Enzymes That Metabolize Xenobiotics
Whitlock, J. P., & Denison, M. S. (1995) · Springer eBooks · doi:10.1007/978-1-4757-2391-5_10 · Cited by 69
Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide
Park, J. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00221-2 · Cited by 68
El-Sankary, W., Bombail, V., Gibson, G. G., & Plant, N. J. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.9.1029 · Cited by 68
Beresford, A. P. (1993) · Drug Metabolism Reviews · doi:10.3109/03602539308993984 · Cited by 67
Sequence variation and phylogenetic history of the mouse Ahr gene
Thomas, R. S., Penn, S. G., Holden, K., Bradfield, C. A., & Rank, D. R. (2002) · Pharmacogenetics · doi:10.1097/00008571-200203000-00009 · Cited by 67
Rifampin reduces plasma concentrations and effects of zolpidem*
Villikka, K., Kivistö, K. T., Luurila, H., & Neuvonen, P. J. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90082-5 · Cited by 64
Induction and drug development
Smith, D. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00107-x · Cited by 63
Difficulties in Anticoagulation Management during Coadministration of Warfarin and Rifampin
Lee, C. R., & Thrasher, K. A. (2001) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.15.1240.33897 · Cited by 61
Sense and Nonsense in the Prediction of Drug-Drug Interactions
Lin, J. H. (2000) · Current Drug Metabolism · doi:10.2174/1389200003338947 · Cited by 61
Self-citationEffect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride
Niemi, M., Kivistö, K. T., Backman, J. T., & Neuvonen, P. J. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00295.x · Cited by 60
Effect of pentobarbital on the disposition of alprenolol
Alván, G., Piafsky, K. M., Lind, M., & von Bahr, C. (1977) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1977223316 · Cited by 60
ROLE OF GLUCOCORTICOID RECEPTOR AND CONSTITUTIVE ANDROSTANE RECEPTOR
Gerbal‐Chaloin, S., Daujat‐Chavanieu, M., Pascussi, J., Pichard‐Garcia, L., Vilarem, M., & Maurel, P. (2002) · Cited by 59
Induction of propranolol metabolism by rifampicin.
Herman, R., Nakamura, K., Wilkinson, G., & Wood, A. (1983) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1983.tb02218.x · Cited by 58
Parkinson, A., Thomas, P. E., Ryan, D. E., & Levin, W. (1983) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(83)90025-5 · Cited by 58
Functional analysis of the transcriptional promoter for the CYP1A1 gene.
Jones, K. W., & Whitlock, J. P. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.10.5098 · Cited by 58
Santostefano, M. J., Ross, D. G., Savas, Ü., Jefcoate, C. R. E., & Birnbaum, L. S. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6389 · Cited by 56
Caraco, Y., Sheller, J. R., & Wood, A. J. J. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36560-7 · Cited by 54
Krusekopf, S., Roots, I., Hildebrandt, A. G., & Kleeberg, U. (2003) · Xenobiotica · doi:10.1080/0049825021000023978 · Cited by 51
White, L. N. H., Davies, A. M., Smith, L. L., Dawson, S., & Matteis, F. D. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90372-4 · Cited by 50
Hepatic Cytochrome P450 Degradation: Mechanistic Diversity of the Cellular Sanitation Brigade
Correia, M. A. (2003) · Drug Metabolism Reviews · doi:10.1081/dmr-120023683 · Cited by 50
Rabbit Pregnane X Receptor Is Activated by Rifampicin
Savas, Ü., Wester, M. R., Griffin, K. J., & Johnson, E. F. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15096-9 · Cited by 47
Kukielka, E., & Cederbaum, A. I. (1994) · Biochemical Journal · doi:10.1042/bj3020773 · Cited by 46
Juan, D., Worwag, E. M., Schoeller, D. A., Kotake, A. N., Hughes, R. L., & Frederiksen, M. C. (1986) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1986.162 · Cited by 45
Takahashi, H., Kashima, T., Kimura, S., Murata, N., Takaba, T., Iwade, K., Abe, T., Tainaka, H., Yasumori, T., & Echizen, H. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15043-x · Cited by 45
Marc, N., Galisteo, M., Lagadic‐Gossmann, D., Fautrel, A., Joannard, F., Guillouzo, A., & Corcos, L. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01083.x · Cited by 44
Effects of benzimidazole derivatives on cytochrome P450 1A1 expression in a human hepatoma cell line
Krusekopf, S., Kleeburg, U., Hildebrandt, A. G., & Ruckpaul, K. (1997) · Xenobiotica · doi:10.1080/004982597240721 · Cited by 44
Interaction of Rifampin and Warfarin
Self, T. H., & Mann, R. B. (1975) · CHEST Journal · doi:10.1378/chest.67.4.490 · Cited by 41
Concentrations and effects of zopiclone are greatly reduced by rifampicin
Villikka, K., Kivistö, K. T., Lamberg, T. S., Kantola, T., & Neuvonen, P. J. (1997) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1997.00579.x · Cited by 39
Lin, J. H., Chiba, M., Chen, I.-W., Nishime, J. A., deLuna, F. A., Yamazaki, M., & Lin, Y. J. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15044-1 · Cited by 37
Self-citation2,3,7,8-Tetrachlorodibenzo-p-dioxin: Potent anticarcinogenic activity in CD-1 mice
DiGiovanni, J., Berry, D. L., Juchau, M. R., & Slaga, T. J. (1979) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(79)91752-2 · Cited by 33
Identification of novel splice variants of ARNT and ARNT2 in the rat
Korkalainen, M., Tuomisto, J., & Pohjanvirta, R. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00489-3 · Cited by 32
Influence of meso‐caval shunt surgery on verapamil kinetics, bioavailability and response.
Eichelbaum, M. F., Albrecht, M., Kliems, G., Schafer, K., & Somogyi, A. A. (1980) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1980.tb01800.x · Cited by 32
Rifampicin Treatment Greatly Increases the Apparent Oral Clearance of Qninidine
Damkier, P., Hansen, L. L., & Brøsen, K. (1999) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1999.tb02019.x · Cited by 32
Hemeryck, A., Vriendt, C. D., & Belpaire, F. M. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200008000-00007 · Cited by 31
Davis, S. S. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00283-7 · Cited by 31
The effect of single dose of rifampicin on the pharmacokinetics of oral nifedipine
Ndanusa, B. U., Mustapha, A., & Abdu‐Aguye, I. (1997) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/s0731-7085(97)00044-7 · Cited by 28
EFFECTS OF AVASIMIBE ON CYTOCHROME P450 2C9 EXPRESSION IN VITRO AND IN VIVO
Sahi, J., Stern, R. H., Milad, M. A., Rose, K., Gibson, G., Zheng, X., Stilgenbauer, L., Sadagopan, N., Jolley, S. L., Gilbert, D., et al. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000208 · Cited by 28
Degawa, M., Kobayashi, K., Miura, S., Arai, H., Esumi, H., Sugimura, T., & Hashimoto, Y. (1992) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1992.tb02720.x · Cited by 24
Role of induction of specific hepatic cytochrome P450 isoforms in epoxidation of 4-vinylcyclohexene.
Fontaine, S. M., Hoyer, P. B., Halpert, J. R., & Sipes, I. G. (2001) · PubMed · Cited by 22
Principles, Mechanisms and Biological Consequences of Induction
(1990) · De Gruyter eBooks · doi:10.1515/9783112563304 · Cited by 22
Induction of rat liver bilirubin-conjugating enzymes and glutathione s-transferase by rifampicin
Adachi, Y., Nanno, T., Yamashita, M., Ueshima, S., & Yamamoto, T. (1985) · Gastroenterologia Japonica · doi:10.1007/bf02776672 · Cited by 20
Multivesicular liposomes for oral delivery of recombinant human epidermal growth factor
Li, H., An, J. H., Park, J., & Han, K. (2005) · Archives of Pharmacal Research · doi:10.1007/bf02973888 · Cited by 20
Induction of Human Drug-Metabolizing Enzymes: Mechanisms and Implications
Ranis, M., & lngelman-Sundberg, M. (1999) · CRC Press eBooks · doi:10.1201/b13995-11 · Cited by 20
Effect of rifampicin on the mouse hepatic mixed-function oxidase system
Tredger, J. M., Smith, H. M., Powell-Jackson, P. R., Davis, M., & Williams, R. L. (1981) · Biochemical Pharmacology · doi:10.1016/0006-2952(81)90440-8 · Cited by 19
In Vitro Models for Early Studies of Drug Metabolism
Lin, J. H., & Rodrigues, A. D. (2001) · Wiley eBooks · doi:10.1002/9783906390437.ch14 · Cited by 17
Self-citationEpidemiology of passive smoke: a prospective study in 589 children.
Stefano, M. D., Miceli, E., Mazzocchi, S., Tana, P., & Corazza, G. R. (2005) · PubMed · Cited by 17
Some Plasma and Saliva Pharmacokinetics Parameters of Rifampicin in the Presence of Pefloxacin
Orisakwe, O. E., Akunyili, D., Agbasi, P. U., & Ezejiofor, N. A. (2004) · American Journal of Therapeutics · doi:10.1097/01.mjt.0000117523.18923.4a · Cited by 15
Stoltz, C. M., & Anderson, A. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00367-0 · Cited by 13
Principles, mechanisms and biological consequences of induction
(1992) · Comparative Biochemistry and Physiology Part A Physiology · doi:10.1016/0300-9629(92)90556-6 · Cited by 12
In Vitro Screening of Cytochrome P450 Induction Potential
Pelkonen, O., Hukkanen, J., Honkakoski, P., Hakkola, J., Viitala, P., & Raunio, H. (2002) · Springer eBooks · doi:10.1007/978-3-662-04383-7_6 · Cited by 8
Lafont, O. (2002) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(02)01366-1 · Cited by 7
Erratum to Ritonavir: clinical pharmacokinetics and interactions with other anti-HIV agents
Hsu, A., Granneman, G. R., & Bertz, R. (1998) · Clinical Pharmacokinetics · doi:10.1007/bf03259712 · Cited by 6
Jeong, H. G., & Yang, K. (1996) · Cancer Letters · doi:10.1016/s0304-3835(06)80031-5 · Cited by 5
Research works printed but not linked: 27
- H. V. Gelboin, 1980, Pharmacol. Rev., 60, 1107
- J. M. Silva, 1998, Drug Metab. Dispos., 26, 490
- W. El-Sankary, 2001, Drug Metab. Dispos., 29, 1499
- R. C. Pollenz, 1994, Mol. Pharmacol., 45, 428
- J.-M. Passcussi, 2000, Mol. Pharmacol., 58, 1441, 10.1124/mol.58.6.1441 · doi:10.1124/mol.58.6.1441 · Paper page
- T. A. Kocarek, 1995, Drug Metab. Dispos., 23, 415
- S. M. Fontaine, 2001, Drug Metab. Dispos., 29, 1236
- J. L. Barwick, 1996, Mol. Pharmacol., 50, 10
- T. Shimada, 1994, J. Pharmacol. Exp. Ther., 270, 414
- K. E. Thummel, 1994, J. Pharmacol. Exp. Ther., 271, 557
- M. F. Paine, 1997, J. Pharmacol. Exp. Ther., 283, 1552
- E. T. Morgan, 2001, Drug Metab. Dispos., 29, 207
- T. K. Chang, 1997, Cancer Res., 57, 1946
- A. Poland, 1990, Mol. Pharmacol., 38, 306
- G. R. Wilkinson, 1987, Pharmacol. Rev., 39, 1
- N. Holtbecker, 1996, Drug Metab. Dispos., 24, 1121
- S. Gerbal-Chaloin, 2001, Drug Metab. Dispos., 29, 242
- L. Drocourt, 2001, Drug Metab. Dispos., 29, 1325
- S. C. Nallami, 2003, Epilepsia, 44, 1428
- I. Waziers de, 1990, J. Pharmacol. Exp. Ther., 253, 387
- R. A. O'Reilly, 1987, Adv. Exp. Med. Biol., 214, 205
- Y. Caraco, 1997, J. Pharmacol. Exp. Ther., 281, 330
- W. D. Fiske, D. Mayers, and K. Wagner. Pharmacokinetics of DMP 266 and indinavir multiple oral doses in HIV-1 infected individuals [abstract no. 568]. 4th Conference on Retroviruses and Opportunistic Infections. 1996, Jan 28–Feb 1. Washington, DC.
- A. H. Conney, 2003, Cancer Res., 63, 7005
- A. Cantani, 2005, Eur. Rev. Med. Pharmacol. Sci., 9, 23
- M. Morimoto, 1995, Hepatology, 21, 1610
- E. L. LeCluyse, 1996, Model Systems for Biopharmaceutical Assessment of Drug Absorption and Metabolism, 125
Cited by
A liver-on-a-chip platform with bioprinted hepatic spheroids
Bhise, N. S., Manoharan, V., Massa, S., Tamayol, A., Ghaderi, M., Miscuglio, M., Lang, Q., Shrike Zhang, Y., Shin, S. R., Calzone, G., et al. (2016) · Biofabrication · doi:10.1088/1758-5090/8/1/014101 · Cited by 615
Obach, R. S., Walsky, R. L., & Venkatakrishnan, K. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.012633 · Cited by 460
The mechanisms of pharmacokinetic food-drug interactions – A perspective from the UNGAP group
Koziolek, M., Alcaro, S., Augustijns, P., Basit, A. W., Grimm, M., Hens, B., Hoad, C. L., Jedamzik, P., Madla, C. M., Maliepaard, M., et al. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.04.003 · Cited by 385
Organotypic liver culture models: meeting current challenges in toxicity testing
LeCluyse, E. L., Witek, R. P., Andersen, M. E., & Powers, M. J. (2012) · Critical Reviews in Toxicology · doi:10.3109/10408444.2012.682115 · Cited by 363
Predicting Drug-Target Interaction Networks Based on Functional Groups and Biological Features
He, Z., Zhang, J., Shi, X.-H., Hu, L.-L., Kong, X., Cai, Y.-D., & Chou, K.-C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009603 · Cited by 288
Metadata
- Authors
- Lin, J. H.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Lin, Jiunn H.
- ORCID
- Lin, Jiunn H.
- Venue
- Pharmaceutical Research
- Published
- 2006-05-26
- Volume
- 23
- Issue
- 6
- Pages
- 1089-1116
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W1997271604
- Cited by
- 264
- References
- 257
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 7 · 2023: 3 · 2022: 10 · 2021: 11 · 2020: 13 · 2019: 7 · 2018: 8 · 2017: 9 · 2016: 11 · 2015: 13 · 2014: 11 · 2013: 15 · 2012: 22
- FWCI
- 3.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Pharmaceutical Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- cytochrome P450 induction, drug interactions, CYP inducers, in vitro-in vivo extrapolation, pharmacokinetics, pharmacodynamics, drug discovery, drug development, treatment efficacy
- MeSH terms
- Pregnane X Receptor, Constitutive Androstane Receptor, Animals, Drug Interactions, Enzyme Induction, Humans, Liver, Pharmacokinetics, Pharmacology, Receptors, Steroid, Species Specificity, Transcription Factors, Genetic Variation, Drug Design, Receptors, Cytoplasmic and Nuclear, Receptors, Aryl Hydrocarbon, Cytochrome P-450 CYP2B1, Cytochrome P-450 CYP2E1, Receptor Cross-Talk, Cytochrome P-450 CYP3A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.